The National Comprehensive Cancer Network (NCCN) 2012 guidelines for NSCLC treatment stated that EGFR mutation analysis and ALK gene rearrangement detection should not be routinely recommended for SQCLC [5]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.